This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alonso, M. Articles by Newcomb, E. W. Search for Related Content PubMed PubMed Citation Articles by Alonso, M. Articles by Newcomb, E. W.

Microsatellite Instability Occurs in Distinct Subtypes of Pediatric but not Adult Central Nervous System Tumors¹

Departments of Pathology [M. A., K. P., T. S., P. P., D. C. M., E. W. N.] and Environmental Medicine [M. K.], Division of Neuropathology [D. C. M.], and the Kaplan Comprehensive Cancer Center [M. K., D. C. M., E. W. N.], New York University School of Medicine, New York, New York 10016, and Institut National de la Santé et de la Recherche Médicale U434-Centre d’Etude de Polymorphisme Humane, 75010 Paris, France [R. H.]

Length alterations in microsatellite repeats, termed microsatellite instability (MSI), are found in 10–15% of sporadic colon, endometrial, and gastric cancers harboring defects in DNA mismatch repair (MMR) genes. We used the microsatellite markers Big Adenine Tract (BAT) 26 and BAT-25 from the reference panel of five markers recommended by the National Cancer Institute to evaluate the incidence of MSI in 206 central nervous system tumors. We screened 102 pediatric and 104 adult cases representing 165 astrocytic and 41 nonastrocytic tumors. The overall incidence of MSI was 8% (16 of 206). All 16 tumors with MSI were found in pediatric rather than adult patients. MSI was associated with two distinct subtypes of pediatric tumors occurring in 27% (12 of 45) of WHO grade III and grade IV astrocytomas and 24% (4 of 17) of gangliogliomas. We evaluated the difference in clinicopathological and genetic features among 45 high-grade pediatric astrocytomas by MSI status. The median survival for pediatric patients with MSI (n = 12) was 8 months compared with 15 months for those patients without MSI (n = 33; P = 0.18). The frequency of p53 gene mutations was 13% for pediatric patients with MSI (n = 8) compared with 47% for those patients without MSI (n = 19; P = 0.19). These results revealed a trend between MSI status and prognosis and MSI status and frequency of p53 gene mutations. Our data suggest that pediatric high-grade astrocytomas can be attributed to two different genetic pathways: a MMR-deficient pathway and a MMR-proficient pathway.

This article has been cited by other articles:

				M. Viana-Pereira, I. Almeida, S. Sousa, B. Mahler-Araujo, R. Seruca, J. Pimentel, and R. M. Reis Analysis of microsatellite instability in medulloblastoma Neuro-oncol, January 1, 2009; 11(5): 458 - 467. [Abstract] [Full Text] [PDF]

				A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al. Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718. [Abstract] [Full Text] [PDF]

				M. Nakamura, K. Shimada, E. Ishida, T. Higuchi, H. Nakase, T. Sakaki, and N. Konishi Molecular pathogenesis of pediatric astrocytic tumors Neuro-oncol, April 1, 2007; 9(2): 113 - 123. [Abstract] [Full Text] [PDF]

				D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045. [Abstract] [Full Text] [PDF]

				A. Broniscer, S. J. Baker, A. N. West, M. M. Fraser, E. Proko, M. Kocak, J. Dalton, G. P. Zambetti, D. W. Ellison, L. E. Kun, et al. Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children J. Clin. Oncol., February 20, 2007; 25(6): 682 - 689. [Abstract] [Full Text] [PDF]

				T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544. [Abstract] [Full Text] [PDF]

				A. Broniscer and A. Gajjar Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist Oncologist, April 1, 2004; 9(2): 197 - 206. [Abstract] [Full Text] [PDF]